Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial. J of Skin 2022, 6 (6), s47. https://doi.org/10.25251/skin.6.supp.47.